| HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer G Rinnerthaler, SP Gampenrieder, R Greil International journal of molecular sciences 20 (5), 1115, 2019 | 210 | 2019 |
| Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer M Gnant, F Fitzal, G Rinnerthaler, GG Steger, S Greil-Ressler, M Balic, ... New England Journal of Medicine 385 (5), 395-405, 2021 | 120 | 2021 |
| Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future SP Gampenrieder, G Rinnerthaler, R Greil Journal of oncology 2013 (1), 732047, 2013 | 118 | 2013 |
| Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry SP Gampenrieder, G Rinnerthaler, C Tinchon, A Petzer, M Balic, S Heibl, ... Breast Cancer Research 23 (1), 112, 2021 | 99 | 2021 |
| Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer F Huemer, G Rinnerthaler, T Westphal, H Hackl, G Hutarew, ... Oncotarget 9 (23), 16512, 2018 | 86 | 2018 |
| miR-16-5p is a stably-expressed housekeeping microRNA in breast cancer tissues from primary tumors and from metastatic sites G Rinnerthaler, H Hackl, SP Gampenrieder, F Hamacher, C Hufnagl, ... International journal of molecular sciences 17 (2), 156, 2016 | 82 | 2016 |
| Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24) GG Steger, R Greil, A Lang, M Rudas, F Fitzal, B Mlineritsch, BL Hartmann, ... Annals of oncology 25 (2), 366-371, 2014 | 78 | 2014 |
| Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free … SP Gampenrieder, A Peer, C Weismann, M Meissnitzer, G Rinnerthaler, ... Breast Cancer Research 21, 1-11, 2019 | 71 | 2019 |
| Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer R Bartsch, C Wenzel, SP Gampenrieder, U Pluschnig, G Altorjai, M Rudas, ... Cancer chemotherapy and pharmacology 62, 903-910, 2008 | 65 | 2008 |
| Baseline absolute lymphocyte count and ECOG performance score are associated with survival in advanced non-small cell lung cancer undergoing PD-1/PD-L1 blockade F Huemer, D Lang, T Westphal, SP Gampenrieder, G Hutarew, L Weiss, ... Journal of clinical medicine 8 (7), 1014, 2019 | 59 | 2019 |
| Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis SP Gampenrieder, F Romeder, C MUß, M Pircher, S Ressler, ... Anticancer research 34 (1), 227-233, 2014 | 49 | 2014 |
| Persistence of ctDNA in patients with breast cancer during neoadjuvant treatment is a significant predictor of poor tumor response Q Zhou, SP Gampenrieder, S Frantal, G Rinnerthaler, CF Singer, D Egle, ... Clinical Cancer Research 28 (4), 697-707, 2022 | 35 | 2022 |
| Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial T Westphal, G Rinnerthaler, SP Gampenrieder, J Niebauer, J Thaler, ... Cancer medicine 7 (12), 5962-5972, 2018 | 35 | 2018 |
| DNA methylation signatures predicting bevacizumab efficacy in metastatic breast cancer SP Gampenrieder, G Rinnerthaler, H Hackl, W Pulverer, A Weinhaeusel, ... Theranostics 8 (8), 2278, 2018 | 35 | 2018 |
| Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer R Bartsch, C De Vries, U Pluschnig, P Dubsky, Z Bago-Horvath, ... BMC cancer 9, 1-10, 2009 | 30 | 2009 |
| Cure in metastatic breast cancer T Westphal, SP Gampenrieder, G Rinnerthaler, R Greil memo-Magazine of European Medical Oncology 11, 172-179, 2018 | 29 | 2018 |
| Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer SP Gampenrieder, R Bartsch, P Matzneller, U Pluschnig, P Dubsky, ... Breast Care 5 (3), 158-162, 2010 | 25 | 2010 |
| ASCO 2018 highlights: metastatic breast cancer G Rinnerthaler, SP Gampenrieder, R Greil memo-Magazine of European Medical Oncology 11, 276-279, 2018 | 23 | 2018 |
| Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes V Domenyuk, Z Gatalica, R Santhanam, X Wei, A Stark, P Kennedy, ... Nature communications 9 (1), 1219, 2018 | 21 | 2018 |
| Long-term outcomes of adjuvant denosumab in breast cancer M Gnant, S Frantal, G Pfeiler, GG Steger, D Egle, R Greil, F Fitzal, V Wette, ... NEJM evidence 1 (12), EVIDoa2200162, 2022 | 18 | 2022 |
